Galip Can Uyar/LinkedIn
Jul 4, 2025, 05:48
Galip Can Uyar: Givastomig plus Nivolumab plus mFOLFOX in Metastatic GEC (Phase I/II)
Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared a post on X:
“Givastomig + Nivolumab + mFOLFOX in mGEC (Phase I/II).
- Bispecific CLDN18.2/4-1BB antibody
- ORR: 71% (up to 83% in expansion cohorts)
- Active in both low PD-L1 and low CLDN18.2
- Well-tolerated at all doses
- Deep, durable responses
- Ongoing 12 mg/kg.”
More posts featuring Galip Uyar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 4, 2025, 05:39
Jul 4, 2025, 05:35
Jul 4, 2025, 05:30
Jul 4, 2025, 05:05
Jul 4, 2025, 04:59
Jul 4, 2025, 04:53